Goldman, Butterwick, Fitzpatrick and Groff
gbfg.comTotal trials
40
Active
11
Phase 3
4
Total enrollment
919
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 9 of 9 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Right leg treated with Glycerin compounded with 1% Lidocaine and Epinephrine | — | — | — | — | — | 1 | |
| Left leg treated with Glycerin compounded with 1% Lidocaine and Epinephrine | — | — | — | — | — | 1 | |
| Sham Comparator | — | — | — | — | 2 | ||
| Babor Ultimate ECM Repair Serum | — | — | — | — | — | 1 | |
| Babor Cure Cream | — | — | — | — | — | 1 | |
| CE Ferulic | — | — | — | — | — | 1 | |
| Pavise Serum | — | — | — | — | — | 1 | |
| On GLP1 plus HRT | — | — | — | — | — | 1 | |
| On GLP1 Only | — | — | — | — | — | 1 |
Next readouts
- 2024-12-31
- 2025-03-05
- 2026-05-30
- 2026-07-30
- 2026-08-30
Top conditions
- Wrinkle5
- Skin Laxity4
- Laxity; Skin3
- Leg Veins2
- Melasma1
- Skin Neoplasms1
- Lax Skin1
- Knee1
Frequently asked questions about Goldman, Butterwick, Fitzpatrick and Groff
- How many clinical trials does Goldman, Butterwick, Fitzpatrick and Groff have on ClinicalTrials.gov?
- Goldman, Butterwick, Fitzpatrick and Groff is listed as the lead sponsor on 40 clinical trials in ClinicalTrials.gov, 11 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Goldman, Butterwick, Fitzpatrick and Groff's trials are in Phase 3?
- 4 of Goldman, Butterwick, Fitzpatrick and Groff's trials are in Phase 3, spread across 9 active drug programs.
- What therapeutic areas does Goldman, Butterwick, Fitzpatrick and Groff focus on?
- Goldman, Butterwick, Fitzpatrick and Groff's most-studied conditions on ClinicalTrials.gov are Wrinkle, Skin Laxity, Laxity; Skin, Leg Veins, Melasma.
- When are Goldman, Butterwick, Fitzpatrick and Groff's next clinical trial readouts?
- Goldman, Butterwick, Fitzpatrick and Groff has 5 upcoming primary-completion readouts tracked here; the soonest is “Skin Care Regimen for Improving Photoaging Signs on the Face”, expected around 2024-12-31.